Monday, April 28, 2014
Since its first "Big
Thinkers" review in 1998, and most recently at the beginning of 2009,
BioCentury has chronicled big pharma's attempts to improve innovation and
reinvent itself through blockbuster mergers and new business models (see
BioCentury, Feb. 2, 2009).
Last week provided yet another
declaration of strategic intent by three large pharmas